Although the short-term effect of newly developed anti-VEGF therapy is encouraging, a large percentage of patients do not respond favorably to these therapies, suggesting there are unknown mechanisms that regulate retinal NV in diabetes (reviewed in [55]). This evidence concerns the gene VEGFA and diabetes mellitus.